drugset / Trial / NCT00559026
Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients
Phase 1
Completed
10 enrolled
Italian National Institute of Health
Regina Elena Cancer Institute · collabUniversity of Rome Tor Vergata · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase I/II study is directed at evaluating safety and immunogenicity of a melanoma peptide vaccine in combination or not with Dacarbazine administration in melanoma patients
Timeline
- Start
- 2004-09
- Primary completion
- —
- Completion
- 2006-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Melan-A | Vaccine | 250 ug | Intrathecal |
| Comparator | gp100 antigen | Peptide | 250 ug | Intrathecal |
| Comparator | IFN-α | Unknown | 3e+06 iu | Subcutaneous |
| Comparator | incomplete Freund's adjuvant | Other / unclassified | — | — |